| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.6 |